Loading clinical trials...
Loading clinical trials...
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Conditions
Interventions
[18F]MNI-815 (MNI-815)
Locations
1
United States
Molecular NeuroImaging, LLC
New Haven, Connecticut, United States
Start Date
May 1, 2015
Primary Completion Date
July 1, 2016
Completion Date
August 1, 2016
Last Updated
December 16, 2016
NCT07422857
NCT07316413
NCT07136844
NCT06891716
NCT06114745
NCT04570761
Lead Sponsor
Molecular NeuroImaging
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions